These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11366793)

  • 1. Transfer therapy--Nevirapine for protease problems?
    TreatmentUpdate; 1999 Jun; 11(4):6-7. PubMed ID: 11366793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
    Martínez E; Conget I; Lozano L; Casamitjana R; Gatell JM
    AIDS; 1999 May; 13(7):805-10. PubMed ID: 10357379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nevirapine (Viramune): a new HIV inhibitor].
    De Wit S; Sternon J; Clumeck N
    Rev Med Brux; 1999 Apr; 20(2):95-9. PubMed ID: 10335104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
    Ena J; Leach A; Nguyen P
    HIV Med; 2008 Oct; 9(9):747-56. PubMed ID: 18651856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch study of nevirapine.
    AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
    Tebas P; Yarasheski K; Henry K; Claxton S; Kane E; Bordenave B; Klebert M; Powderly WG
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):589-94. PubMed ID: 15242534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease therapy and changes to insulin and glucose.
    TreatmentUpdate; 1999 Jun; 11(4):5-6. PubMed ID: 11366792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment options.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are changes in body shape linked to viral load.
    TreatmentUpdate; 1999 Jun; 11(4):4-5. PubMed ID: 11366791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
    Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
    AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E
    J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
    [No Abstract]   [Full Text] [Related]  

  • 16. '96-'97 new drugs and the nominees for 1997 are...
    Notes Undergr; 1997; (No 35):suppl 1-2. PubMed ID: 11364566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
    Petit JM; Duong M; Masson D; Buisson M; Duvillard L; Bour JB; Brindisi MC; Galland F; Guiguet M; Gambert P; Portier H; Vergès B
    Eur J Clin Invest; 2004 Aug; 34(8):569-75. PubMed ID: 15305892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.